The trial achieved its main goal with a statistically significant and clinically relevant improvement in PFS.
Columvi therapy provides a much-needed, off-the-shelf, fixed-duration alternative for transplant ineligible individuals.
Phase 3 tests showing Dupixent dramatically decreased itching and hives when compared to a placebo led to approval.
In a Phase 3 trial, orforglipron, the first small molecule GLP-1, successfully reduced A1C by an average of 1.3% to 1.6% across dosages.
Lecanemab is the only approved Aβ monoclonal antibody that binds and clears hazardous protofibrils.
All nine subjects of phase 1 injected without any serious adverse events.
Data from the danuglipron clinical development program will be presented at a scientific meeting or published in a peer-reviewed journal in the future.
Tolebrutinib was generally well tolerated by all subjects across all study arms.
IMDELLTRA’s safety profile was consistent with the recognized profile. Detailed DeLLphi-304 results will be presented at an upcoming medical congress.
The FDA’s animal testing requirement will be decreased, modified, or potentially replaced utilizing a variety of methodologies.
